The first Alzheimer's-related changes begin to develop some 25 years before memory and thinking problems appear, according to a new study that may offer a valuable guide for companies looking to test new treatments in people at an earlier stage.
The study, published on Wednesday in the New England Journal of Medicine, offers a timeline of changes in spinal fluid, brain size, the appearance of brain plaques and other factors that precede the onset of Alzheimer's in people who are genetically predestined to develop the brain-wasting disease.
"It's really the first report that we have in living people of these changes," said Dr. Randall Bateman of Washington University School of Medicine in St. Louis, Missouri who helped lead the study.
Current drugs for Alzheimer's only treat symptoms and none have yet been able to keep the fatal disease from progressing. Some researchers think that may be because the disease has been studied too late in its progression.
So scientists have been searching for ways to test treatments at an earlier stage, when many researchers think new therapies will have the best shot at doing some good.
Conducting such trials in people with the common form of Alzheimer's disease would need to be huge and last for decades.
Instead, the study by the team at Washington University focuses on families enrolled in the Dominantly Inherited Alzheimer's Network, a consortium that enrolls people who are genetically predisposed to develop the disease at an early age.
"On average, patients with this form get Alzheimer's Disease by 45," Bateman said in a telephone interview.
People in these families have a 50 percent chance of inheriting one of three genes that cause early Alzheimer's and most develop symptoms around the same time as their affected parent.
Bateman followed the progress of 129 individuals and used family histories to estimate when study subjects should begin to develop Alzheimer's symptoms. They developed a timeline of changes in the body leading up to the memory loss and declines in thinking skills associated with Alzheimer's.
The first of these changes, a drop in the level of a protein known as amyloid, can be detected in spinal fluid as early as 25 years before the disease is expected to develop.
At 15 years before onset of the disease, clumps of an Alzheimer's-related protein called beta amyloid become visible on brain scans. Other scans show shrinkage of brain structures, and levels of a toxic protein called tau start to rise in spinal fluid.
At 10 years before onset, the brain becomes less adept at using glucose and some slippage in certain kinds of memory skills can be detected.
Bateman said it is not clear whether the same timeline would apply to patients who have more common late-onset Alzheimer's disease, which usually develops after age 65. But he said the biomarkers are very similar to changes already used by doctors to characterize and track the disease.
"What we don't know is if the time, the order of magnitude and the size of these changes is similar or not," Bateman said. "It may be many years before we have this information."
Researchers plan to use information from the study to test drugs on these patients before symptoms develop.
Crenezumab, an experimental Alzheimer drug made by Roche's Genentech unit has already been selected for a similar kind of test in a large family of people in Colombia who develop early onset Alzheimer's disease.
While Bateman would not say which drugs will be tested in the study, he said they will likely test three compounds "that we think represent some of the best and most advanced compounds in development."
Results of two of the most advanced drugs being studied are expected this fall. They include late-stage studies of bapineuzumab being developed by Pfizer and Johnson & Johnson, and solanezumab, being developed by Eli Lilly .
Another drug in late-stage trials is intravenous immunoglobulin, an immune system treatment being studied by Baxter International Inc.
As many as five million Americans have Alzheimer's and the clock is ticking to find a cure.
Experts predict that without an effective treatment, the number of Americans with Alzheimer's will double by 2050 to more than 10 million, and related healthcare costs could soar to over $1 trillion a year.
More than 100,000 people -- half of them children -- die every year due to waterborne diseases, experts say
Located in the bustling Adjame quarter of Ivory Coast's main city and commercial hub, the haven for fake medicine has been targeted time and again by authorities and stockpiles burnt.
Seven firms to receive ecolabel certifying that their products are environment-friendly
Disasters saddle U.S. with $306 billion price tag, cause 362 deaths
Association for Prevention of Drug Abuse head says close to more than 2.5 million children are drug addicts in Bangladesh
King penguins are certainly accustomed to chilly weather, more so than species like the Humboldt that prefer somewhat warmer climes, said zoo curator Malu Celli.
Some eight million children and teenagers across the Southeast Asian nation will receive the shot to prevent further spread of the disease which is caused by a bacterial infection.
Two players vomited on the pitch, and play had to be halted briefly.
French pharmaceutical giant Sanofi announced Wednesday that its world-first dengue vaccine could lead to more severe symptoms for people who had not previously been infected.
Doctors Worldwide Turkey says it has performed 3,000 cataract surgeries in Horn of Africa country
Over 40,000 cases of cholera seen in Democratic Republic of Congo since July, says Health Ministry
Decked out in red to signify their "Stop Coal" campaign, the protesters chanted and beat drums as they snaked through the former West Germany capital toward the UN centre that will host the 12-day, 196-nation talks, tasked with implementing the landmark Paris Agreement.
The Greenhouse Gas Bulletin, the UN weather agency's annual flagship report, tracks the continent of dangerous gasses in atmosphere in the post-industrial era (since 1750).
£10 ($13) tax introduced to cut British capital's poor air-pollution records
Despite all-out efforts to give the Chinese Communist Party blue skies for its twice-a-decade congress, Beijing's notorious smog has cloaked the mega-city in its trademark toxic haze.
Equipment donation to children's oncology institute is first project of state-run aid agency TIKA in Brazil